Evolent Health (EVH) Tops Q1 EPS by 5c, Offers Guidance

Evolent Health (NYSE: EVH) reported Q1 EPS of ($0.01), $0.05 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $215.1 million versus the consensus estimate of $212.79 million.

GUIDANCE:

Evolent Health sees Q2 2021 revenue of $210-225 million, versus the consensus of $212 million.

Evolent Health sees FY2021 revenue of $845-880 million, versus the consensus of $865 million.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Bernstein SocGen on StandardAero Inc (SARO): ' Solid revenues, but short-term margin issues'
• US Tiger Securities Reiterates Hold Rating on Pinduoduo Inc. (PDD)